Please login to the form below

Not currently logged in
Email:
Password:

FCB

This page shows the latest FCB news and features for those working in and with pharma, biotech and healthcare.

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications

Secondary endpoints included change from baseline in BCVA at 48 weeks, change from baseline in FCB retinal thickness at 48 weeks, safety and immunogenicity.

Latest news

More from news
Approximately 12 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...